Australija - engleski - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 500 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australija - engleski - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 2000 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australija - engleski - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 250 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australija - engleski - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 1000 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in adults with haemophilia b,2) treatment and prevention of bleeding episodes in adults with haemophilia b (congenital factor ix deficiency),3) peri-operative management in adults with haemophilia b 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Australija - engleski - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - nonacog gamma, quantity: 3000 iu - injection, powder for - excipient ingredients: histidine; sodium chloride; calcium chloride dihydrate; mannitol; sucrose; polysorbate 80 - 1) routine prophylaxis of bleeding episodes in patients with haemophilia b 2) treatment and prevention of bleeding episodes in patients with haemophilia b (congenital factor ix deficiency) 3) peri-operative management in patients with haemophilia b

Kanada - engleski - Health Canada

quest vitamins a div of purity life health products - gamma-linolenic acid (evening primrose oil); d-alpha tocopherol; vitamin a; vitamin d3; linoleic acid (evening primrose oil) - capsule - 80mg; 25unit; 2500unit; 100unit; 280mg - gamma-linolenic acid (evening primrose oil) 80mg; d-alpha tocopherol 25unit; vitamin a 2500unit; vitamin d3 100unit; linoleic acid (evening primrose oil) 280mg - multivitamin preparations

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

energique, inc. - .gamma.-aminobutyric acid (unii: 2acz6ipc6i) (.gamma.-aminobutyric acid - unii:2acz6ipc6i), levodopa (unii: 46627o600j) (levodopa - unii:46627o600j), norepinephrine (unii: x4w3enh1cv) (norepinephrine - unii:x4w3enh1cv), serotonin (unii: 333do1rdjy) (serotonin - unii:333do1rdjy), corticotropin (unii: k0u68q2txa) (corticotropin - unii:k0u68q2txa), semecarpus anacardium juice (unii: y0f0bu8rdu) (semecarpus anacardium juice - unii:y0f0bu8rdu), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - un - .gamma.-aminobutyric acid 6 [hp_x] in 1 ml - for temporary relief of symptoms of attention deficit disorder, learning disabilities and hyperactivity.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration. for temporary relief of symptoms of attention deficit disorder, learning disabilities and hyperactivity.** **these statements are based upon traditional homeopathic practice. they have not been reviewed by the food and drug administration.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

apotheca company - .gamma.-aminobutyric acid (unii: 2acz6ipc6i) (.gamma.-aminobutyric acid - unii:2acz6ipc6i), norepinephrine (unii: x4w3enh1cv) (norepinephrine - unii:x4w3enh1cv), serotonin (unii: 333do1rdjy) (serotonin - unii:333do1rdjy), semecarpus anacardium juice (unii: y0f0bu8rdu) (semecarpus anacardium juice - unii:y0f0bu8rdu), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), barium carbonate (unii: 6p669d8hq8) (barium cation - unii:v645272hln), oyster shell calcium carbonate, crude (u - .gamma.-aminobutyric acid 30 [hp_c] in 1 ml - indications:   for temporary relief of symptoms of attention deficit disorder, learning disabilities and hyperactivity. indications:   for temporary relief of symptoms of attention deficit disorder, learning disabilities and hyperactivity.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

horizon therapeutics usa, inc. - interferon gamma-1b (unii: 21k6m2i7ag) (interferon gamma-1b - unii:21k6m2i7ag) - interferon gamma-1b 100 ug in 0.5 ml - - actimmune is indicated for reducing the frequency and severity of serious infections associated with chronic granulomatous disease (cgd). - actimmune is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis (smo). actimmune is contraindicated in patients who develop or have known hypersensitivity to interferon gamma, e. coli derived products, or any component of the product. risk summary there are no adequate and well-controlled studies in pregnant women. actimmune should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. animal data actimmune has shown an increased incidence of abortions in primates when given from gestation day 20 to 80 in doses approximately 100 times the human dose. a study in pregnant primates treated with subcutaneous doses 2 – 100 times the human dose failed to demonstrate teratogenic activity for actimmune. female mice treated subcutaneously with recombinant murine ifn-interferon gamma (rmuifn-gamma) at 280 times the maximum recommended clinical dose of actimmune from shortly after birth through puberty but not during pregnancy had offspring which exhibited decreased body weight during the lactation period. the clinical significance of this finding observed following treatment of mice with rmuifn-gamma is uncertain. for lower doses, there is no evidence of maternal toxicity, embryotoxicity, fetotoxicity or teratogenicity in preclinical studies. risk summary it is not known whether actimmune is excreted in human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from actimmune, a decision should be made whether to discontinue nursing or to discontinue the drug, dependent upon the importance of the drug to the mother. infertility based on the information available, it cannot be excluded that the presence of higher levels of interferon gamma may impair male fertility and that in certain cases of female infertility increased levels of interferon gamma may have played a role [see nonclinical toxicology (13.1) ]. in younger patients, the long-term effect on fertility is also not known. the safety and effectiveness of actimmune has been established in pediatric patients aged 1 year and older in cgd patients and 1 month and older in smo patients [see clinical studies (14)]. there are no data available for pediatric patients below the age of 1 month. clinical studies of actimmune did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

apotheca company - .gamma.-aminobutyric acid (unii: 2acz6ipc6i) (.gamma.-aminobutyric acid - unii:2acz6ipc6i) - .gamma.-aminobutyric acid 30 [hp_c] in 1 ml - indications:   to be used according to standard homeopathic indications. indications: to be used according to standard homeopathic indications.